Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

Bacterial CpG-DNA activates dendritic
cells in vivo: T helper cell-independent
cytotoxic Tcell responses to soluble proteins.
Eur J Immunol 2000; 30: 3591±
3597.
118 Vabulas, R. M., Pircher, H., Lipford,
G. B., Hacker, H. and Wagner, H.
CpG-DNA activates in vivo T cell epitope
presenting dendritic cells to trigger
protective antiviral cytotoxic T cell responses.
J Immunol 2000; 164: 2372±
2378.
119 Chu, R. S.,Targoni, O. S., Krieg, A. M.,
Lehmann, P. V. and Harding, C. V.
CpG oligodeoxynucleotides act as adjuvants
that switch on T helper 1 (Th1) immunity.
J Exp Med 1997; 186: 1623±
1631.
120 Roman, M., Martin-Orozco, E.,
Goodman, J. S., et al. Immunostimulatory
DNA sequences function as
T helper-1-promoting adjuvants [see
Comments]. Nat Med 1997; 3: 849±854.
121 Wild, J., Grusby, M. J., Schirmbeck, R.
and Reimann, J. Priming MHC-I-restricted
cytotoxic T lymphocyte responses
to exogenous hepatitis B surface
antigen is CD4 + T cell dependent.
J Immunol 1999; 163: 1880±1887.
122 Davis, H. L.,Weeratna, R., Waldschmidt,
T. J., et al. CpG DNA is a potent
enhancer of specific immunity in
mice immunized with recombinant hepatitis
B surface antigen [published erratum
appears in J Immunol 1999;
162(5): 3103]. J Immunol 1998; 160:
870±876.
123 Weiner, G. J., Liu, H. M., Wooldridge,
J. E., Dahle, C. E. and
Krieg, A. M. Immunostimulatory
oligodeoxynucleotides containing the
CpG motif are effective as immune adjuvants
in tumor antigen immunization.
Proc Natl Acad Sci USA 1997; 94:
10833±10837.
124 Sun, S., Kishimoto, H. and Sprent, J.
DNA as an adjuvant: capacity of insect
DNA and synthetic oligodeoxynucleotides
to augment T cell responses to
specific antigen. J Exp Med 1998; 187:
1145±1150.
125 Kim, S. K., Ragupathi, G., Musselli, C.,
et al. Comparison of the effect of different
immunological adjuvants on the
References
antibody and T-cell response to immunization
with MUC1±KLH and GD3±KLH
conjugate cancer vaccines. Vaccine 1999;
18: 597±603.
126 Liu, H. M., Newbrough, S. E.,
Bhatia, S. K., et al. Immunostimulatory
CpG oligodeoxynucleotides enhance
the immune response to vaccine
strategies involving granulocyte-macrophage
colony-stimulating factor. Blood
1998; 92: 3730±3736.
127 Davila, E. and Celis, E. Repeated administration
of cytosine-phosphorothiolated
guanine-containing oligonucleotides
together with peptide/protein immunization
results in enhanced CTL
responses with anti-tumor activity. JImmunol
2000; 165: 539±547.
128 Egeter, O., Mocikat, R., Ghoreschi, K.,
Dieckmann, A. and Rocken, M. Eradication
of disseminated lymphomas with
CpG-DNA activated T helper type 1 cells
from nontransgenic mice. Cancer Res
2000; 60: 1515±1520.
129 Brunner, C., Seiderer, J., Schlamp, A.,
et al. Enhanced dendritic cell maturation
by TNF-a or cytidine-phosphate-guanosine
DNA drives Tcell activation in vitro
and therapeutic anti-tumor immune responses
in vivo. J Immunol 2000; 165:
6278±6286.
130 Wooldridge, J. E., Ballas, Z.,
Krieg, A. M. and Weiner, G. J. Immunostimulatory
oligodeoxynucleotides
containing CpG motifs enhance the
efficacy of monoclonal antibody therapy
of lymphoma. Blood 1997; 89: 2994±
2998.
131 Warren, T. L., Dahle, C. E. and Weiner,
G. J. CpG oligodeoxynucleotides
enhance monoclonal antibody therapy
of a murine lymphoma. Clin Lymphoma
2000; 1: 57±61.
132 Jahrsdorfer, B., Hartmann, G., Racila,
E., et al. CpG DNA increases primary
malignant B cell expression of
costimulatory molecules and target
antigens. J Leuk Biol 2001; 69: 81±88.
133 Decker, T., Schneller, F., Sparwasser,
T., et al. Immunostimulatory
CpG-oligonucleotides cause proliferation,
cytokine production, and an immunogenic
phenotype in chronic lym-
285